-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Melanoma with NRAS mutation often has enhanced MAPK pathway signaling and cell cycle checkpoint dysregulation.
Therefore, the combination regimen of MEK inhibitor binimetinib and selective CDK4/6 inhibitor Ribociclib would be a promising strategy.
a reasonable joint solution
.
.
This is an open-label Phase Ib/II clinical trial to evaluate the initial activity and safety of ribocillin in combination with bimetinib in NRAS-mutated melanoma
.
The primary endpoint of Phase Ib is to determine the maximum tolerated dose of the combination regimen and the recommended Phase II dose (RP2D), and the primary endpoint of Phase II is the antitumor activity of the combination regimen (RP2D)
Between June 27, 2013, and November 10, 2016, a total of 102 patients were enrolled: 61 in the dose-escalation phase and 41 in the dose-expansion phase
.
In the first cycle of Phase Ib, 10 (16.
Progression-free survival in patients at different stages
Progression-free survival in patients at different stagesIn the phase II cohort (n=41), the overall response rate was 19.
5%
.
The response rate was 32.
The overall response rate was 19.
Treatment response in patients with different mutations
Treatment response in patients with different mutationsCommon treatment-related toxicities were increased creatine phosphokinase, rash, edema, anemia, nausea, diarrhea, and fatigue
.
The results of the pharmacokinetic and safety analyses were consistent with those of the single-agent studies, suggesting that there was no interaction between the two drugs
In conclusion, the combination regimen of bimetinib and ribocillin can be safely used in NRAS-mutated melanoma patients with positive therapeutic activity
.
Cell cycle gene co-mutations may be used to screen patients who would benefit more from this regimen
The combination regimen of bimetinib and ribocillin can be safely used in patients with NRAS-mutated melanoma and has positive therapeutic activity .
Original source:
Original source:Martin Schuler, et al.
leave a message here
